Core Insights - ARS Pharmaceuticals is showcasing the clinical advancements and real-world usability of neffy, a needle-free epinephrine delivery system, at the 2026 AAAAI Annual Scientific Meeting [1][2] - The nasal epinephrine has a longer shelf life compared to auto-injectors, leading to a more affordable price point [1] - Patient preference for the nasal option increased by over 25% due to the aversion to needle-based administration [1] Group 1: Clinical Presentations - Five poster presentations and one healthcare professional case report will focus on neffy, highlighting health-economic analyses, patient preference research, and pharmacokinetic comparisons with injectable epinephrine [1][2] - The presentations will demonstrate that neffy 2 mg exposure is comparable to 0.5 mg intramuscular injection, indicating potential cost-effectiveness and patient preference [2] Group 2: Poster Presentation Details - The first poster will discuss the societal value of nasal epinephrine due to needle aversion [3] - The second poster will compare the pharmacokinetics and pharmacodynamics of nasal spray and intramuscular injection [3] - The third poster will focus on treatment preferences between nasal epinephrine and autoinjectors among food-allergic patients [3][4] - Additional posters will address the importance of characteristics of epinephrine treatments and treatment adherence related to nasal versus autoinjector options [4] Group 3: HCP Case Report and Partner Presentations - A healthcare professional case report will evaluate the effectiveness of intranasal epinephrine in routine allergy practice [5] - Late-breaking partner presentations will explore device portability and user preferences between epinephrine autoinjectors and nasal delivery systems [6]

Core Insights - The Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation, has been successfully initiated in Canada, aiming to compare its bioavailability and pharmacokinetics against EpiPen for anaphylaxis treatment [2][3][4] - Interim results from the Phase 2 study are expected in the first quarter of 2026, which will provide insights into the efficacy and safety of NS002 [3][4] Group 1: Study Details - The Phase 2 study is an open-label, fixed-sequence trial involving 50 healthy adults with a history of allergic rhinitis [3] - The study is designed to evaluate pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen [3] Group 2: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [5] - The company's proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [5] Group 3: Market Need - The development of NS002 addresses the need for user-friendly treatment options for patients with severe allergies, particularly those who fear needles or find traditional autoinjectors cumbersome [4]